A Phase III, Multicenter, Randomized, Open-Label Study of Atezolizumab (Anti-PD-L1 Antibody) Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
Latest Information Update: 12 Jun 2025
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary)
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms IMbrave050
- Sponsors Roche
Most Recent Events
- 27 Oct 2023 Results assessing the efficacy of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with high-risk hepatocellular carcinomapublished in the Internet Document
- 24 Jun 2023 Results (n=334) assessing safety and patient-reported outcomes from IMbrave050 presented at the European Association for the Study of the Liver Congress 2023
- 06 Jun 2023 Results of PRO outcomes presented at the 59th Annual Meeting of the American Society of Clinical Oncology